Polymyositis is a rare, chronic inflammatory myopathy characterized by progressive muscle weakness, primarily affecting the proximal muscles such as those of the shoulders, hips, and thighs. It is considered an autoimmune disorder in which the body&rsquo;s immune system mistakenly attacks healthy muscle fibers, leading to inflammation, degeneration, and impaired muscle function. The disease most commonly affects adults, with a higher prevalence in females, and can significantly impact mobility, daily functioning, and overall quality of life. In some cases, polymyositis may also be associated with other autoimmune conditions or underlying malignancies, making early diagnosis clinically important.
From a <a href="https://www.delveinsight.com/report-store/polymyositis-market">Polymyositis Market</a> perspective, the polymyositis treatment landscape remains relatively limited due to the rarity of the condition and lack of disease-specific approved therapies. As a result, treatment strategies largely rely on off-label and symptomatic management approaches. The increasing awareness of rare autoimmune diseases and advancements in immunology research are driving interest in the development of targeted therapies. Additionally, rising healthcare expenditure and improved diagnostic capabilities are contributing to better identification of patients, thereby expanding the potential patient pool within the global market.
The current treatment paradigm for polymyositis primarily includes corticosteroids such as prednisone as first-line therapy to control inflammation. In cases where patients show inadequate response or experience relapses, immunosuppressive agents like methotrexate, azathioprine, and mycophenolate mofetil are commonly used. Intravenous immunoglobulin (IVIG) therapy may also be considered for severe or refractory cases. In recent years, biologic therapies and novel immunomodulatory agents have gained attention in clinical research, offering potential for improved outcomes and reduced long-term steroid dependence.
Overall, the polymyositis market is expected to witness gradual growth, driven by ongoing research into autoimmune mechanisms, increasing pipeline activity in inflammatory muscle diseases, and a growing focus on precision medicine approaches for rare disorders.
&nbsp;

Polymyositis Market 

Polymyositis Market Infographic

Polymyositis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape